Keywords: Ceohalon, Second-quarter 2011 financial results, Teva
Cephalon reports disappointing 2nd-qtr 2011 results, ahead of completion of acquisition by Teva
Article | 04 August 2011
US biotech firm Cephalon (Nasdaq: CEPH), the subject of a $6.8 billion takeover deal from Israeli generics giant Teva Pharmaceutical Industries ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
